Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.48 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.48 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CETP | P11597 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28235038 | 1.00 | MAPK1 (0.49) | MAPK1LGALS3LGALS8LGALS4L3MBTL1 | |
| SCHEMBL30232023 | 1.00 | MAPK1 (0.49) | MAPK1LGALS3LGALS8LGALS4L3MBTL1 | |
| SCHEMBL12908201 | 0.94 | MAPK1 (0.56) | MAPK1LGALS3LGALS8LGALS4CETP | |
| SCHEMBL28862276 | 0.94 | MAPK1 (0.56) | MAPK1LGALS3LGALS8LGALS4CETP | |
| SCHEMBL28156231 | 0.94 | MAPK1 (0.56) | MAPK1LGALS3LGALS8LGALS4CETP | |
| SCHEMBL23545823 | 0.94 | MAPK1 (0.56) | MAPK1LGALS3LGALS8LGALS4CETP | |
| SCHEMBL19498843 | 0.94 | MAPK1 (0.56) | MAPK1LGALS3LGALS8LGALS4CETP | |
| SCHEMBL30231904 | 0.94 | MAPK1 (0.56) | MAPK1LGALS3LGALS8LGALS4CETP | |
| SCHEMBL927214 | 0.94 | MAPK1 (0.56) | MAPK1LGALS3LGALS8LGALS4CETP | |
| SCHEMBL28156223 | 0.94 | MAPK1 (0.56) | MAPK1LGALS3LGALS8LGALS4CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7344704-B2 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi | SCHERING AG (DE) | 2008-03-18 | — | — | US | disclosed |
| US-20070269384-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media for diagnosis of Alzheimer's disease | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070269384-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media for diagnosis of Alzheimer's disease | APP, APBA1, PSEN1 | MAPK1 2810/4885LGALS3 714/4885LGALS8 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.